China Healthcare Weekly (Oct.20)-Investment Returns on Weight Loss/AD,GLP-1 Gene Therapy,AIM Vaccine
⬇ $AIM Vaccine(06660)$ - Weight loss and Alzheimer's disease (AD) would generate different investment returns.We're conservative about the outlook of GLP-1 gene therapy.We consider AIM Vaccine risky and recommend staying away
Continue reading on Smartkarma:- https://www.smartkarma.com/insights/china-healthcare-weekly-oct-20-investment-returns-on-weight-loss-ad-glp-1-gene-therapy-aim-vaccine?utm_source=tiger_community
By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community
On AIM Vaccine (06660):- https://www.smartkarma.com/entities/aim-vaccine-co-ltd?utm_source=tiger_community
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
